# Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

> **NCT03975231** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 6 (estimated)

## Conditions studied

- BRAF NP_004324.2:p.V600E
- BRAF V600K Mutation Present
- Thyroid Gland Anaplastic Carcinoma

## Interventions

- **DRUG:** Dabrafenib
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03975231
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-14
- **Primary completion:** 2027-10-05
- **Final completion:** 2027-10-05
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03975231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03975231, "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03975231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*